Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6) > Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6):609-24



To subscribe PROMO
Submit an article
Recommend to your librarian





Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6):609-24


language: English

Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis

Girolomoni G. 1, Vena G. A. 2, Ayala F. 3, Cannavò S. P. 4, De Pità O. 5, Chimenti S. 6, Peserico A. 7

1 Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy; 2 Unit of Dermatology and Venereology, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 3 Department of Dermatology and Venereology, Medical School of Naples Federico II University, Naples, Italy; 4 Section of Dermatology, Department of Social Medicine, University of Messina, Messina, Italy; 5 Department of Immunology and Allergology, Istituto Dermopatico dell’Immacolata, IRCSS, Rome, Italy; 6 Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy; 7 Unit of Dermatology, Department of Medicine, University of Padoa, Padoa, Italy


Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the efficacy and safety of their fixed combination has been provided by randomized, double-blind, controlled clinical trials involving more than 7000 patients with the ointment formulation in psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These trials have shown that the fixed combination ointment is more effective and better tolerated, not only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, in most instances, to be more effective than betamethasone and at least as well tolerated. The same applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of treatment with the fixed combination for up to one year produce systemic effects. Studies have also shown that the fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency. Because of the extensive evidence, American and European guidelines recommend the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp.

top of page